Abbott Laboratories (ABT) Earnings Date & Reports

Key Takeaways

• Adjusted EPS of $1.31 beat the Wall Street consensus estimate of $1.28 by 2.34%, rising 4% from $1.26 a year ago.
• Revenue reached $12.59 billion, exceeding the $12.48 billion consensus and climbing 13% year over year, while comparable sales grew 4.8%.
• Medical Devices led the quarter with 8.4% comparable sales growth, fueled by electrophysiology, diabetes care, and heart failure products.
• Full-year 2026 adjusted EPS guidance was raised to $5.45–$5.60 from the prior $5.38–$5.58, signaling management confidence in second-half momentum.
• ABT shares rose approximately 3.2% in pre-market trading following the release, and BTIG subsequently raised its price target to $134.

Earnings Context and Why It Matters

Abbott Laboratories' second-quarter 2026 report carried outsized significance for investors navigating a complex healthcare landscape. Coming off a first quarter where the company narrowly beat estimates with $1.15 in adjusted EPS and $11.16 billion in revenue, the Q2 release was seen as a litmus test for whether Abbott's diversified portfolio — spanning medical devices, diagnostics, nutrition, and established pharmaceuticals — could sustain momentum despite lingering softness in its nutrition segment and broader macroeconomic uncertainty. The quarter also included a full contribution from the Exact Sciences acquisition, which closed in March 2026, making this the first reporting period where investors could assess the deal's impact on the diagnostics business. With the stock down roughly 28% year-to-date ahead of the report, the stakes for a convincing beat were high.

Reported Results

Abbott reported second-quarter 2026 adjusted earnings per share (EPS) of $1.31, surpassing the Zacks Consensus Estimate of $1.28 and landing at the top end of management's own guidance range of $1.25 to $1.31. On a GAAP (Generally Accepted Accounting Principles) basis, EPS came in at $0.53. Total revenue of $12.59 billion beat analyst expectations of $12.48 billion, representing 13% growth on a reported basis. Comparable operational sales — which strip out currency effects and acquisition impacts — rose 4.8%, an acceleration from the 3.7% comparable growth posted in the first quarter.

By segment, Medical Devices was the standout performer, generating $5.85 billion in sales and 8.4% comparable growth. Electrophysiology delivered low-teens growth, while Rhythm Management and Heart Failure grew 9.5% and 9%, respectively. Diabetes Care, anchored by Abbott's FreeStyle Libre continuous glucose monitoring (CGM) franchise, grew 9.5% with CGM sales surpassing $2 billion. Diagnostics revenue surged 42.3% on a reported basis to $3.09 billion, largely reflecting the Exact Sciences acquisition. On a comparable basis, diagnostics grew 2.9%, led by a 13.3% jump in Cancer Diagnostics, which includes the Cologuard colon cancer screening test. Core Laboratory Diagnostics grew 3.2%, while Rapid and Molecular Diagnostics declined 8% due to a weaker respiratory virus season.

Established Pharmaceuticals (EPD) posted 8.7% comparable growth to $1.5 billion, driven by strong demand in India, Latin America, and Southeast Asia. Nutrition remained the soft spot, with sales declining 3.6% on a comparable basis to $2.14 billion. U.S. nutrition sales fell 9%, though the segment showed a sequential improvement of $127 million from the first quarter. Adjusted gross margin expanded approximately 100 basis points (1 percentage point) to 58.0%.

Abbott raised its full-year 2026 adjusted EPS guidance to a range of $5.45 to $5.60, up from $5.38 to $5.58 previously, while reaffirming comparable sales growth guidance of 6.5% to 7.5%. For the third quarter, management guided to adjusted EPS of $1.38 to $1.46.

AI Screener

Staying on top of earnings seasons, sector rotations, and breakout candidates across thousands of stocks can be a time-intensive challenge for any investor. Tickeron's AI Screener addresses that challenge by offering an AI-powered stock and ETF discovery tool that lets users filter the market using customizable criteria such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener scans thousands of equities and ETFs in real time, helping traders and investors identify trade ideas, trending stocks, and breakout candidates far more efficiently than manual screening alone. For investors monitoring healthcare names like Abbott Laboratories alongside the broader market, the AI Screener can surface opportunities aligned with specific strategies and risk preferences. Explore what the AI Screener can uncover for your watchlist.

Market Reaction and Investor Sentiment

Abbott shares climbed approximately 3.2% in pre-market trading on July 16, reflecting investor relief that the company delivered a clean beat and an upward guidance revision. The stock had entered the earnings event under considerable pressure, trading roughly 28% below its 52-week high and facing concerns about potential headwinds from Affordable Care Act subsidy cuts and softer nutrition demand. Analysts responded favorably: BTIG raised its price target from $131 to $134 and maintained a Buy rating, while Benchmark reiterated its Buy rating and $120 target ahead of the release. Broader sentiment appeared to take comfort in CEO Robert Ford's characterization of an accelerating business and management's confidence that Abbott's chronic-disease-focused portfolio is less vulnerable to insurance coverage disruptions than hospital-centric peers.

Forward Outlook and Key Factors to Monitor

Abbott enters the second half of 2026 with tangible momentum across its highest-growth franchises. Management pointed to several catalysts expected to drive an acceleration in sales and profit growth, including new product launches such as the Libre Duo — a dual glucose and ketone monitoring sensor — and the TactiFlex Duo pulsed field ablation (PFA) catheter for treating atrial fibrillation. These launches are strategically timed to reinforce Abbott's positions in diabetes care and electrophysiology, two of the company's fastest-growing markets.

Investors should monitor whether the Nutrition segment can sustain its sequential recovery. While the $127 million quarter-over-quarter improvement is encouraging, the segment's 9% U.S. decline highlights ongoing challenges tied to pricing actions and competitive dynamics. Progress here will be a key variable in whether gross margins can continue expanding toward the upper end of management's implied range.

The Exact Sciences integration also warrants close attention. With Cancer Diagnostics posting 13.3% comparable growth and Cologuard achieving mid-teens expansion, the acquisition appears to be delivering as promised. However, sustained double-digit growth in this unit will be necessary to justify the $23 billion deal price and offset declines in Rapid and Molecular Diagnostics. Additionally, Abbott flagged ongoing pressure in its China business tied to volume-based procurement (VBP) policies, a factor that could weigh on EPD growth rates over the coming quarters. Together, these dynamics create a balanced risk-reward profile that investors will continue to evaluate as quarterly results unfold.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations